Particle.news
Download on the App Store
3 ARTICLES
·
5d ago

Lotte Biologics Secures First ADC Manufacturing Deal, Launches Full-Scale Operations

The $100 million cGMP ADC facility in New York begins operations with a contract to produce a clinical-stage cancer therapy for an Asia-based biotech company.

This undated file photo provided by Lotte Biologics Co. shows Syracuse Bio Campus in New York. (PHOTO NOT FOR SALE) (Yonhap)

Overview

  • Lotte Biologics has signed its first manufacturing agreement for an antibody-drug conjugate (ADC) with an Asia-based biotech firm, marking the start of full-scale operations at its Syracuse Bio Campus.
  • The newly completed $100 million ADC facility features a 1,000-liter conjugation reactor, integrated production and purification lines, and in-house quality control testing.
  • This contract officially launches the company's ADC contract development and manufacturing organization (CDMO) services, offering end-to-end support from clinical development to commercial production.
  • Lotte Biologics aims to expand its client base and partnerships while also constructing a new bio plant in Incheon, South Korea, set to begin operations in 2027.
  • The company plans to achieve ₩1.5 trillion (US$1.05 billion) in sales by 2030 and become one of the top 10 global CDMOs, supported by ongoing infrastructure investments and strategic growth initiatives.